Lazanda 2017 U.S. PROMOTIONAL AUDIT REPORT

Published July 2018 • 30 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Lazanda through reportable promotional activity in 2017 and how does this compare to its peer set in the Cancer Pain and Pain – Opioids markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Depomed’s depth of coverage vary within key specialties (e.g., Radiation Oncology, Anesthesiology, Pain Medicine, Hematology/Oncology, Physical Medicine and Rehabilitation, Internal Medicine, and Family Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Lazanda throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Lazanda in 2017?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. More than four years of longitudinal data is available – covering payments to more than 975,000 U.S. healthcare professionals.
• Over 600 paid interactions across 300 physicians made on behalf of Lazanda were carefully examined to support our analysis. In addition, interaction data from 17 peer products (e.g. Abstral, Arymo ER, Belbuca, Butrans, Embeda, Fentanyl Patch, Hysingla ER, Ionsys, Levorphanol, Morphabond ER, Nucynta, Oxaydo, OxyContin, Primlev, Subsys, Xtampza ER, and Zohydro ER ) was leveraged to provide benchmarking and market insights.